New Ideas.
Better Results.

Blue Matter is a consulting firm serving the life sciences industry. We strive to bring a new approach to consulting with original ideas that deliver a meaningful impact.

Contact Us

Our Purpose

We are proud to be part of an industry that is pushing the boundaries of science and technology to improve people’s lives. Our role is to help our clients identify unique insights, generate new ideas and drive meaningful results to get the most out of their products, portfolios and teams.

We began our careers in established consulting firms where we developed valuable experience and industry knowledge. During this time, we came to see that rigid processes often interfered with original thinking and led to bloated deliverables packed with mediocre answers.

A group of us like-minded, passionate consultants believed there was a better approach and founded Blue Matter to provide a platform to foster innovation and creativity in consulting.

Our Difference

Industry and scientific knowledge, analysis and insights. Left brain thinking. This is the foundation of our discipline. Creativity and imagination. Constantly challenging conventional thinking and seeking fresh ideas. Right brain thinking. We’re passionate about this; it’s the reason our clients come back.

The key to winning is effective differentiation. And effective differentiation comes from originality–thinking that is grounded in reason and infused with imagination.

"The terrific work you did resulted in a substantial change to our commercial strategy."

- Chairman of the Board, Small Biotech

"Thank you very much for the great work and partnership. You are one of the rare breed of consultants whom I trust. You will always be on my speed dial if we need help with anything."

- Chief Commercial Officer, Small Biotech

"I appreciate all of the great work you have done for our team this past year and look forward to continued partnership in the New Year."

- Chief Commercial Officer, Mid-sized Diagnostic Company

"Your preparation and support has been instrumental in achieving our desired outcome."

- Franchise Commercial Lead, Global Biotech

"Thank you all so much for the extremely successful project...I couldn't be happier with the way that it went."

- Sr. Product Manager, Diagnostic Company

"This project was excellent, from the content development to facilitation. Many, many thanks for the great work!"

- Director of Marketing, Diagnostic Company

"The process was great, I loved that I didn't have to manage you that much. Everything was highly organized and done on time. Quality and originality of thinking was also good."

- Global Commercial Lead, Large Biotech

"Great project. I was learning as we went along; good expertise — brought in examples from other projects."

- Global Commercial Lead, Large Biotech

Our Clients

Our clients include: top global bio-pharmaceutical companies with large, diverse product portfolios to small emerging players with one asset in development, leading diagnostic companies, and investment houses. We work with CEOs, Chief Commercial Officers, Franchise Heads, Product Directors, Functional Area Leaders. 90%+ of our business is from repeat, satisfied customers.

Our Services

Shape Innovative Products

Drive Successful Launches

Build Great Portfolios and Companies

Pathfinder Capabilities

Blue Matter offers in-depth market expertise across North American and European markets.

Our Pathfinder offerings are specifically designed to help growing biopharma companies succeed in European markets.

Learn more: 7 Keys to Success in Europe

Want to Join Our Team?

Blue Matter offers enriching project experiences with a diverse range of strategic, client-facing projects in the exciting and innovative life sciences industry.

Join Our Team


#Biopharma companies thinking about getting into #DigitalTherapeutics should study the chronic insomnia market. It…

What #businessmodels can #pharmaceutical companies use when launching products and building their organizations in…

Expanding a Biotech Business into Europe: Determining Which Model to Use When Launching Your First Product and Building Country Operations in Europe

The biotechnology industry is a booming sector with many new companies researching and developing innovative and specialized medicines. Typically, a startup biotech company will focus its limited resources on R&D and its market of origin (or some other region that’s strategically selected because of its large size and/or market potential).  For a US-based company, that … Read More

How will the change to a more narrow FDA label for Aduhelm (aducanumab) help Biogen?

Varun Renjen, M.D. describes how the recent decision to restrict Aduhelm’s label to earlier-stage patients with mild cognitive impairment (MCI) could be a good thing for Biogen’s new Alzheimer’s therapy. He also outlines three lessons for other pharma companies entering the Alzheimer’s market. Link here Read More

Keeping Biopharma Up At Night: How the Chronic Insomnia Market Raises Big Questions About Digital Therapeutics

The Digital Therapeutics (DTx) space is new and rapidly growing within the healthcare landscape (for a DTx 101: Intro and Overview, see here).  Biopharma companies should carefully consider their potential entry into this space, as their customers will be increasingly engaging with DTx products that have the potential to complement or even compete with biopharma … Read More

What challenges could Biogen’s Aduhelm (aducanumab) face as it goes to market?

Biogen’s Aduhelm® (aducanumab) is the fist potentially disease-modifying therapy approved for Alzheimer’s disease.  However, it could face some significant challenges as it goes to market. Varun Renjen, M.D., describes the three main ones in this short video. Link here. Read More

What impact is Biogen’s Aduhelm (aducanumab) likely to have on the Alzheimer’s Market?

On June 7, 2021, the FDA approved Biogen’s Aduhelm® (aducanumab) for Alzheimer’s disease.  As the first potentially disease-modifying therapy for Alzheimer’s, it could have some significant impacts on the market for Alzheimer’s therapies. Varun Renjen, M.D., outlines those potential impacts in this short video. Link here Read More

Upcoming Webinar: Psychedelics in CNS Therapeutics

Don’t miss this informative webinar on Tuesday, July 20 at 11:00 am EDT. Register here. Psychedelics and other traditionally taboo substances are undergoing a bit of a “renaissance” in central nervous system (CNS) therapeutics. These types of substances have a long and storied history around the world. Now, research into their potential therapeutic benefits is … Read More

Alzheimer’s Disease: An In-Depth Look at a Formidable Foe

There is no shortage of disabling and deadly diseases in the world.  However, few match Alzheimer’s disease (AD) when it comes to sheer ability to cause fear and dread.  It’s not a rare disease.  In fact, it’s on the rise.  There is no cure (nor effective treatment yet) and it’s ultimately fatal.  And, most frightening, … Read More